摘要
目的考察奥扎格雷钠在国人中的药动学过程。方法采用双周期试验设计,选用12名健康志愿者单剂量及多剂量po200 mg奥扎格雷钠口服液,建立HPLC测定奥扎格雷钠的血药浓度并计算药动学参数,进而对主要药动学参数进行统计分析。结果单剂量与多剂量的药-时曲线均符合一级吸收的二房室开放模型,其主要药动学参数AUC0-t分别为(3.50±0.90)与(5.87±1.18)mg·h·L-1,AUC0-∞分别为(3.73±0.91)与(6.32±1.29)mg·h·L-1,ρmax分别为(3.10±1.06)与(5.12±1.37)mg·L-1,tmax分别为(0.42±0.12)与(0.50±0.26)h,t1/2β分别为(0.72±0.26)与(0.75±0.99)h。结论单剂量与多剂量给药的主要药动学参数比较ρmax,AUC0-t,AUC0-∞采用Excel进行成对t检验具有极显著性差异(P<0.01)。
Abstract
OBJECTIVE To study the pharmacokinetic profiles of ozagrel in healthy Chinese volunteers.METHODS In a two period study,12 healthy male volunteers received a single dose and multiple-dose regimen of 200 mg ozagrel.The plasma concentrations of ozagrel were determined by HPLC.The pharmacokinetic parameters of ozagrel were calculated and analyzed with statistical method.RESULTS The concentration-time curves of a single dose and multiple-dose regimen were fit to a two-compartment open model with first-order absorption.The main pharmacokinetic parameters of a single-dose and multiple-dose regimen were as follows:AUC0-t(3.50±0.90)and(5.87±1.18)mg·h·L-1,AUC0-∞(3.73±0.91) and(6.32±1.29) mg·h·L-1,ρmax(3.10±1.06)and(5.12±1.37)mg·L-1,tmax(0.42±0.12)and((0.50±0.26)h),t1/2β(0.72±0.26) and(0.75±0.99)h,respectively.CONCLUSION The statistical analysis shows that there are significant difference after the treatment of a single dose and multiple-dose regimen.
关键词
奥扎格雷钠 /
单剂量 /
多剂量 /
高效液相色谱法 /
药动学
{{custom_keyword}} /
Key words
ozagrel /
single-dose /
multiple-dose /
HPLC /
pharmacokinetic
{{custom_keyword}} /
金锐;孙考祥;王珍;韩毓博.
单剂量及多剂量口服奥扎格雷钠口服液的人体药动学研究[J]. 中国药学杂志, 2006, 41(04): 296-298
JIN Rui;SUN Ko-xing;WNG Zhen;HN Yu-o.
Pharmacokinetic Study on Ozagrel in Twelve Healthy Volunteers [J]. Chinese Pharmaceutical Journal, 2006, 41(04): 296-298
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] SEKI H, KUROMAKI K, TAKEDA S,et al. Trial of prophylactic administration of TXA2 synthetase inhibitor, ozagrel hydrochloride,for preeclampsia[J] .Hypertens Pregnancy,1999,18(2):157-164.
[2] OGISO T, IWAKI M, HARA Y,et al. Pharmacokinetics of ozagrel and its metabolites after intravenous and oral administrations[J] .Pharm Sci,1997,86(10):1111-1114.
[3] ZHENG N X, SATO H, KOBAYSHI F,et al. Rectal absorption of ozagrel from a suppository containing its commercial tablet in healthy human subjects[J] .Biol Pharm Bull,1997,20(3):282-284.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}